RHHBY

Roche Holding Ltd

 
Sponsored ADR (1 ADS : 0.125 Ordinary) International Reporting
OTCQX International Premier
 

OTC Disclosure & News Service

 

Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced l

Dec 07, 2017

OTC Disclosure & News Service

Basel, Switzerland -


This release includes additional documents. Select the link(s) below to view.

inv-update-2017-12-07a-Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer.pdf

Copyright © 2017 OTC Markets. All Rights Reserved


The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.